News und Analysen
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Novocure Reports Second Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and efficacy of Tumor Treating Fields
Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2023 financial results on Wednesday, August 9th, before the market opens. A conference call has been scheduled
Novocure to Report Second Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2023 on Thursday, July 27, 2023, before the U.S. financial markets open. Novocure management
Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the
Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy
Charles River Laboratories International, Inc. (NYSE: CRL) and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, today
Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) and the INADcure Foundation, a nonprofit organization whose mission is to support the development of treatments for Infantile Neuroaxonal
Klinische Phase-3-Studie LUNAR zeigt statistisch signifikante und klinisch bedeutsame Verlängerung des Gesamtüberlebens bei Patienten mit metastasiertem nicht-kleinzelligem Lungenkrebs nach platinbasierten Therapien
Novocure (NASDAQ: NVCR) stellt heute im Rahmen der Jahrestagung der American Society of Clinical Oncology (ASCO) 2023 positive Ergebnisse der klinischen Phase-3-Studie LUNAR zur Prüfung der
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Novocure (NASDAQ: NVCR) today is presenting positive results from the phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard therapies
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6th, at 10:00 a.m. CT
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer®, the ASCO Foundation, to advance cancer research and education.
Conquer Cancer is a global community of
Charles River Laboratories and Wheeler Bio Announce Agreement to Build and Operate RightSourceSM Laboratory
Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), today announced an agreement to implement RightSource
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today
Charles River Laboratories Announces First-Quarter 2023 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9
Xencor Reports First Quarter 2023 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today
Novocure Reports First Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
Charles River Laboratories Launches Next Generation Sequencing Services for Bacterial Identification and Fungal ID
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Accugenix® Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix®
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
Charles River Laboratories International, Inc. (NYSE: CRL) today launched Apollo™, an industry-leading, secure, cloud-based platform for drug developers that provides access to study data, study
Charles River Laboratories to Present at Barclays Global Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15th, at 10:15 a.m. ET. Management